Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-09-20
2010-10-05
Schnizer, Richard (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S455000, C424S093200, C514S055000
Reexamination Certificate
active
07807650
ABSTRACT:
Methods and compositions for the treatment of intestinal disorders, such as IBD and Crohn's disease, are disclosed. Preferred compositions include siNA. Also disclosed is a method of specifically targeting siNA to treat intestinal disorders by intrarectal administration of siNA compounds.
REFERENCES:
patent: 7176304 (2007-02-01), McSwiggen et al.
patent: 2004/0115641 (2004-06-01), Cowsert et al.
patent: 2004/0241843 (2004-12-01), Baker et al.
patent: 2005/0013854 (2005-01-01), Mannino et al.
patent: 2005/0026278 (2005-02-01), Tuschl et al.
patent: 2005/0272682 (2005-12-01), Evers et al.
patent: 2006/0172963 (2006-08-01), Shepard et al.
patent: 2006/0172965 (2006-08-01), Shepard et al.
patent: 2007/0249549 (2007-10-01), Axelsson et al.
patent: 2406568 (2005-04-01), None
patent: WO 03/070744 (2003-08-01), None
patent: WO 2004/029212 (2004-04-01), None
patent: WO 2004/042024 (2004-05-01), None
patent: WO 2005/044976 (2005-05-01), None
patent: WO 2005/045037 (2005-05-01), None
Gersemann, et al. (2008) Crohn's Disease-Defect in Innate Defence. World J. Gastroenerol., v.14(36):5499-503.
Bass, B.L. (2001) The Short Answer. Nature, v.411:428-9.
Rogler, et al. (1998) Cytokines in Inflammatory Bowel Disease. World Journal of Surgery, v.22:382-9.
Borg et al., “NK Cell Activation by Dendritic Cells (DCs) Requires the Formation of a Synapse Leading to IL-12 Polarization in DCs,” Blood, Nov. 15, 2004, 104(10):3267-3275.
Caspi, “Short Analytical Review IL-12 in Autoimmnuity,” Clinical Immunology and Immunopathology, Jul. 1998, 88(1):4-13.
Davidson et al, “IL-12, But Not IFN-γ, Plays a Major Role in Sustaining the Chronic Phase of Colitis in IL-10-Deficient Mice,” The Journal of Immunology, 1998, pp. 3144-3149.
Fais et al., “Interferon Expression in Crohn's Disease Patients: Increased Interferon-γ and -α mRNA in the Intestinal Lamina Propria Mononuclear Cells,” Journal of Interferon Research, 1994, 14:235-238.
Flynn et al., “Efficient Delivery of Small Interfering RNA for Inhibition of IL-12p40 Expression in vivo,” Journal of Inflammation, 2004, 1(4):1-12.
Fuss et al., “Disparate CD4 Lamina Propria (LP) Lymphokine Secretion Profiles in Inflammatory Bowel Disease,” The Journal of Immunology, 1996, pp. 1261-1270.
Gately et al., “The Interleukin-12/Interleukin-12-Receptor System: Role in Normal and Pathologic Immune Responses,” Annual Review of Immunology, 1998, 16:495-521.
Hill et al., “Immune Modulation by Silencing IL-12 Production in Dendritic Cells Using Small Interfering RNA,” The Journal of Immunology, 2003, 171:691-696.
Mannon et al., “Anti-Interleukin-12 Antibody for Active Crohn's Disease,” The New England Journal of Medicine, Nov. 11, 2004, 351(20):2069-2080.
Monteleone et al., Interleukin 12 Is Expressed and Actively Released by Crohn's Disease Intestinal Lamina Propria Mononuclear Cells, Gastroenterology, 1997, 112:1169-1178.
Neurath et al., “Antibodies to Interleukin 12 Abrogate Established Experimental Colitis in Mice,” The Journal of Experimental Medicine, Nov. 1995, 182:1281-1290.
Parronchi et al., “Type 1 T-Helper Cell Predominance and Interleukin-12 Expression in the Gut of Patients with Crohn's Disease,” American Journal of Pathology, Mar. 1997, 150(3):823-832.
Plevy et al., “A Role for TNF-α and Mucosal T Helper-1 Cytokines in the Pathogenesis of Crohn's Disease,” The Journal of Immunology, 1997, 6276-6282.
Simpson et al., “T Cell-mediated Pathology in Two Models of Experimental Colitis Depends Predominantly on the Interleukin 12/Signal Transducer and Activator of Transcription (Stat)-4 Pathway, but Is Not Conditional on Interferon γ Expression T Cells,” J. Exp. Med., Apr. 20, 1998, 187(8):1225-1234.
Trinchieri, “Interleukin-12: A Cytokine at the Interface of Inflammation and Immunity,” Advances in Immunology, 1998, 70:83-243.
Vandenbroeck et al., “Inhibiting Cytokines of the Interleukin-12 Family: Recent Advances and Novel Challenges,” Journal of Pharmacy and Pharmacology, 2004, 56:145-160.
Akashi et al., “Suppression of Gene Expression by RNA Interference in Cultured Plant Cells,” Antisense Nucleic Acid Drug Dev, 2001, 11(6):359-367.
Ambion, Tech Notes 10(4) and siRNA Target Finder (http://www.ambion.com/techlib/misc/siRNA—finder.html, available to the public) retrieved on May 1, 2008, siRNA target hit for SEQ ID No. 139 included.
Banerjee et al., “Control of Developmental Timing by Small Temporal RNAs: a Paradigm for RNA-mediated Regulation of Gene Expression,” Bioessays, 2002, 24(2):119-129.
Bosher et al., “RNA Interference: Genetic Wand and Genetic Watchdog.” Nat Cell Biol, 2000, 2(2):E31-6.
Braasch et al., “Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression,” Biochemistry, 2002, 41(14):4503-4510.
Brummelkamp et al., “A System for Stable Expression of Short Interfering RNAs in Mammalian Cells,” Science, American Association for the Advancement of Science, 2002, 296(5567):550-553.
Caplen et al., “Specific inhibition of Gene Expression by Small Double Stranded RNAs in Invertebrate and Vertebrate Systems,” Proc. Natl. Acad. Sci. USA, 2001,98: 9742-9747.
Denkert et al., “Induction of G0/G1 Cell Cycle Arrest in Ovarian Carcinoma Cells by the Ant-Inflammatory Drug NS-398, but not by COX-2-Specific RNA Interference,” Oncogene, 2003, 22:8653-8661.
Elabashir et al., “Duplexes of 21-Nucleotide RNAs mediate RNA interference in Cultured Mammalian Cells,” Nature, May 24, 2001, 411(6836):494-498.
Elbashir et al., “RNA Interference is Mediated by 21- and 22-Nucleotide RNAs,” Genes Dev, 2001, 15(2):188-200.
Fire et al., “Potent and Specific Genetic Interference by Double Stranded RNA in aCaenorhabditis elegans,” Nature, 1998, 391(6669):806-11.
Ge et al., “RNA Interference of Influenza Virus Production by Directly Targeting mRNA for Degradation and Indirectly Inhibiting all Viral RNA Transcription,” Proc Natl Acad Sci USA., 2003, 100(5):2718-2723.
Gil et al., “Induction of Apoptosis by the dsRNA-dependent Protein Kinase (PKR): Mechanism of Action,” Apoptosis, 2000, 5(2):107-114.
Grosshans et al., “Micro-RNAs: Small is Plentiful,” J Cell Biol, 2002, 156(1):17-21.
Hammond et al., “Post-Transcriptional Gene Silencing By Double-Standed RNA,” Nature, 2001, 2:110-119.
Krutzfeldt et al., “Silencing of microRNAs in vivo with ‘Antagomirs’,” Nature, 2005, 438(7068):685-689.
Mahato et al., “Modulation of Gene Expression by Antisense and Antigene Oligodeoxynucleotides and Small Interfering RNA,” Expert Opinion on Drug Delivery, Jan. 2005, 2(1):3-28.
Miller et al., “Allele-specific Silencing of Dominant Disease Genes,” Proceedings of the National Academy of Sciences of USA, Jun. 10, 2003, 100(12):7195-7200.
Paddison et al., “Short hairpin RNAs (shRNAs) Induce Sequence-Specific Silencing in Mammalian Cells,” Genes Dev, 2002, 16(8):948-958.
Scherer et al., “Approaches for the Sequence-Specific Knockdown of mRNA,” Nat. Biotechnology, 2003, 21(12):1457-1465.
Tuschl et al., “Targeted mRNA degradation by double-stranded RNA in vitro,” Genes Dev., 1999, 13(24):3191-3197.
Uprichard et al., The Therapeutic Potential of RNA Interference, FEBS Letters, Oct. 31, 2005 579(26):5996-6007.
Wetering et al., “Specific Inhibition of Gene Expression Using a Stably Integrated, Inducible Small-Interfering-RNA Vector,” EMBO Reports, Jun. 2003, 4(6):609-615.
Wianny et al., “Specific Interference with Gene Function by Double-Stranded RNA in Early Mouse Development,” Nat Cell Biol, 2000, 2(2):70-75.
Williams BR, “Role of the Double-Stranded RNA-activated Protein kinase (PKR) in Cell Regulation,” Biochem Soc Trans, 1997,
Gascón Irene
Jiménez Ana I.
Jiménez María Concepción
Román José P.
Sesto Angela
Brivanlou Margaret B.
King & Spalding LLP
Pitrak Jennifer
Schnizer Richard
Sylentis S.A.U.
LandOfFree
Methods and compositions for the treatment of intestinal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the treatment of intestinal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment of intestinal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4210921